Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors-Reference-Cited by-同舟云学术

Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38α inhibitors

Published:2021-04 Issue: Volume:215 Page:113277
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Ali Eslam M.H.^ORCID,El-Telbany Rania Farag A.,Abdel-Maksoud Mohammed S.,Ammar Usama M.,Mersal Karim I.,Zaraei Seyed-Omar^ORCID,El-Gamal Mohammed I.,Choi Se-In,Lee Kyung-Tae,Kim Hee-Kwon,Lee Kwan Hyi^ORCID,Oh Chang-Hyun

Funder

Korea Institute of Science and Technology

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference43 articles.

1. Role of MAPKs in development and differentiation: lessons from knockout mice;Aouadi;Biochimie,2006

2. Regulatory mechanisms of mitogen-activated kinase signaling;Zhang;Cell. Mol. Life Sci.,2007

3. Compromised MAPK signaling in human diseases: an update;Kim;Arch. Toxicol.,2015

4. Dual-specificity Phosphatase 5 Controls the Localized Inhibition, Propagation, and Transforming Potential of ERK Signaling;Kidgera,2017

5. Targeting ERK1/2 protein-serine/threonine kinases in human cancers;Roskoski;Pharmacol. Res.,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of RAF kinases and their inhibitors (2019–2023);European Journal of Medicinal Chemistry;2024-09

2. The anticancer therapeutic potential of pyrimidine–sulfonamide hybrids;Future Medicinal Chemistry;2024-04-16

3. Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases;Biochemical Pharmacology;2024-02

4. Anti-inflammatory effect of 3-fluorophenyl pyrimidinylimidazo[2,1-b]thiazole derivatives as p38α inhibitors;Bioorganic Chemistry;2023-10

5. Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022;ACS Omega;2023-07-26